AZP-3601 is a peptide analog of parathyroid hormone (PTH) that targets a specific configuration of the PTH1 receptor to safely produce sustained levels of calcium in the blood and thereby control the symptoms of hypoparathyroidism.1
AZP-3601 has been designed to prevent chronic kidney disease by limiting the amount of calcium eliminated in the urine, and to preserve bone integrity, an important benefit since a large proportion of patients with hypoparathyroidism are middle-aged women often at an increased risk of developing osteoporosis.
AZP-3601 has already demonstrated an optimal pharmacological profile in several preclinical studies.2,3 We have successfully completed pre-investigational new drug activities and a Phase 1 clinical study has been initiated in September 2020.
- Hattersley G, et al. “Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.” Endocrinology 2016; 157:141.
- Shimizu, et al. “Pharmacodynamic Actions of a Long-Acting PTH Analog (LA-PTH) in Thyroparathyroidectomized (TPTX) Rats and Normal Monkeys.” J Bone Miner Res. 2016 Jul;31(7):1405-12.
- Bi, et al. “Diphtheria Toxin- and GFP-Based Mouse Models of Acquired Hypoparathyroidism and Treatment With a Long-Acting Parathyroid Hormone Analog.” J Bone Miner Res. 2016 May;31(5):975-84.
AZP-3601 (red) bound to the PTH1 receptor. Adapted from Zhao et al. Science 364:138, 2019.
Image generated with the PyMOL Molecular Graphics System, Version 2.3.2 Schrödinger, LLC.